Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 589

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 589
---
 value of the common
stock. Initially, the Board reserved 3,977 shares of common stock issuable upon the grant of awards under the 2022 Plan. The 2022 Plan
provides for an automatic increase in the number of shares available for issuance beginning on January 1, 2023 and each January 1 thereafter,
by 4% of the number of outstanding shares of common stock on the immediately preceding December 31, or such number of shares as determined
by the Board of Directors.

On July 16, 2024 and November 6, 2024, our stockholders approved an
increase to the number of shares available under the 2022 Plan by 83,334 shares and 100,000 shares, respectively, which increases were
previously approved by the Board. The total number of shares that remain available for issuance under the 2022 Plan is 57,068 shares effective
as of March 27, 2025, which additional reservation of shares provides us with flexibility to address future equity compensation needs.
This increase is essential to attract and retain qualified employees, directors and consultants, and to align their interests with those
of our stockholders.

EQUITY PLAN INFORMATION

    Plan Category: 
    Number
    of securities to be issued upon exercise or issuance of outstanding options, units, warrants and
    rights(1):  
    Weighted
    average exercise price of outstanding options,  warrants and rights(1) :  
    Number
    of securities remaining available for future issuance(1): 
  
    2022 Equity Incentive Plan: 

    Equity compensation plans approved by security holders 
     4,437  
    $116.07  
     154,392 
  
    Equity compensation plans not approved by security holders 
     —  
     —  
     — 
  
    Total 
     4,437  
    $116.07  
     154,392 

    (1)
    Balances
    presented as of December 31, 2024

45

Purchases of Equity Securities by the Issuer
and Affiliated Purchasers

None.

Item 6. [Reserved]

Not applicable.

Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations

Prospective investors should read the following
discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes
and